Australia markets closed

Veradigm Inc. (MDRX)

OTC Markets EXMKT - OTC Markets EXMKT Delayed price. Currency in USD
Add to watchlist
9.85+0.04 (+0.41%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.81
Open9.80
Bid0.00 x 2900
Ask0.00 x 1000
Day's range9.80 - 9.85
52-week range5.01 - 14.09
Volume11,431
Avg. volume456,466
Market cap1.06B
Beta (5Y monthly)0.63
PE ratio (TTM)11.45
EPS (TTM)0.86
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date07 Oct 2008
1y target est11.40
  • Business Wire

    Black Book ranks Veradigm Payer Analytics the #1 Overall Payer Analytics Solutions Vendor in 2024

    CHICAGO, June 12, 2024--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book Research, a healthcare-centric market research and public opinion research and consulting company, rated Veradigm Payer Analytics the overall number one provider of payer analytics solutions for health plans.

  • Business Wire

    Veradigm Payerpath Rated Highest in Client Satisfaction

    CHICAGO, May 30, 2024--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book Research, a healthcare-centric market research and public opinion research and consulting company, rated Veradigm Payerpath the overall number one provider of claims and clearinghouse platform solutions for small medical practices.

  • Business Wire

    Veradigm Announces Leadership Updates

    CHICAGO, May 28, 2024--Veradigm Inc. (OTCMKTS: MDRX, the "Company"), a leading provider of healthcare data and technology solutions, today announced that, on June 7, 2024, Tom Langan, the Company’s President and Chief Commercial Officer (CCO), will assume the role of interim Chief Executive Officer (CEO), reporting directly to the Executive Chairman and the Board. Mr. Langan has been a Company leader since 2018 and has more than 25 years of life sciences, payer and data & analytics experience. I